An Effectiveness and Safety Study of Intravenous Golimumab in Patients With Active Rheumatoid Arthritis Despite Treatment With Methotrexate Therapy

Completed · Phase 3 · Has a placebo group

Conditions studied: Arthritis, Rheumatoid

In brief

The purpose of this study is to evaluate clinical effectiveness and safety of golimumab with methotrexate (MTX) in the treatment of rheumatoid arthritis (RA) when compared to MTX alone.

Key facts

Study ID

NCT00973479

Run by

Centocor, Inc.

People needed

592

Starts

2009-09-01

Expected to finish

2013-02-01

Last updated by the study team

2013-12-25

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of rheumatoid arthritis (RA) for at least 3 months prior to screening
• Have been treated with and tolerated methotrexate (MTX) at a dose of at least 15 mg/week for at least 3 months prior to screening, and have been on a stable MTX dose of 15 mg/week to 25 mg/week for at least 4 weeks prior to screening
• Have an active RA, as defined by disease activity with at least 6 swollen and 6 tender joints, at the time of screening and at baseline
• C-Reactive Protein greater than or equal to 1.0 mg/dL at screening
• No history of latent or active tuberculosis prior to screening

You may not qualify if…

• Other inflammatory diseases, including but not limited to psoriatic arthritis, ankylosing spondylitis, systemic lupus erythematosus, or lyme disease
• Treated with disease modifying agents (other than methotrexate)/systemic immunosuppressives (eg, D-penicillamine, hydroxychloroquine, chloroquine, oral or parenteral gold, sulfasalazine, leflunomide, azathioprine, cyclosporine, mycophenolate mofetil) during the 4 weeks prior to first administration of study agent
• Received intra-articular (in the joint), intramuscular (in the muscle), or intravenous corticosteroids, including adrenocorticotropic hormone, during the 4 weeks prior to first administration of study agent
• Known allergy to human immunoglobulin proteins or other components of golimumab
• Received any commercial or investigational anti-tumor necrosis factor alpha therapy such as but not exclusively infliximab, golimumab, adalimumab or etanercept

Where it is running

• Study site — Miami, Florida, United States
• Study site — Palm Harbor, Florida, United States
• Study site — Moline, Illinois, United States
• Study site — Wheaton, Maryland, United States
• Study site — Worcester, Massachusetts, United States
• Study site — Lincoln, Nebraska, United States
• Study site — Cincinnati, Ohio, United States
• Study site — Lubbock, Texas, United States
• Study site — Buenos Aires, Argentina
• Study site — Córdoba, Argentina
• Study site — Rosario, Argentina
• Study site — San Juan, Argentina
• Study site — San Miguel de Tucumán, Argentina
• Study site — Santa Fe, Argentina
• Study site — Cairns, Australia
• Study site — Maroochydore, Australia
• Study site — Melbourne, Australia
• Study site — Woodville, Australia
• Study site — Woolloongabba, Australia
• Study site — Antioquia, Colombia
• Study site — Barranquilla, Colombia
• Study site — Bogotá, Colombia
• Study site — Cali Valley Del Cauca, Colombia
• Study site — Medellín, Colombia
• Study site — Daytona Beach, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.